Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies.

Stasiłojć G, Felberg A, Urban A, Kowalska D, Ma S, Blom AM, Lundin J, Österborg A, Okrój M.

J Immunol Methods. 2020 Jan;476:112675. doi: 10.1016/j.jim.2019.112675. Epub 2019 Oct 17.

2.

Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.

Felberg A, Urban A, Borowska A, Stasiłojć G, Taszner M, Hellmann A, Blom AM, Okrój M.

Cancer Immunol Immunother. 2019 Apr;68(4):587-598. doi: 10.1007/s00262-019-02304-0. Epub 2019 Feb 6.

3.

SHOC1 is a ERCC4-(HhH)2-like protein, integral to the formation of crossover recombination intermediates during mammalian meiosis.

Guiraldelli MF, Felberg A, Almeida LP, Parikh A, de Castro RO, Pezza RJ.

PLoS Genet. 2018 May 9;14(5):e1007381. doi: 10.1371/journal.pgen.1007381. eCollection 2018 May.

4.

Parameters critical for the effector mechanism of anti-CD20 antibodies revisited.

Stasiłojć G, Felberg A, Okrój M.

Br J Haematol. 2018 Mar;180(6):777-779. doi: 10.1111/bjh.15130. Epub 2018 Feb 7. No abstract available.

PMID:
29411875
5.

Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays.

Urban A, Borowska A, Felberg A, van den Heuvel L, Stasiłojć G, Volokhina E, Okrój M.

Autoimmunity. 2018 Feb;51(1):18-24. doi: 10.1080/08916934.2017.1423286. Epub 2018 Jan 8.

PMID:
29308663
6.

The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.

de Castro RO, Previato L, Goitea V, Felberg A, Guiraldelli MF, Filiberti A, Pezza RJ.

J Biol Chem. 2017 May 19;292(20):8459-8471. doi: 10.1074/jbc.M117.778183. Epub 2017 Apr 5.

7.

A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age.

Ahsan H, Halpern J, Kibriya MG, Pierce BL, Tong L, Gamazon E, McGuire V, Felberg A, Shi J, Jasmine F, Roy S, Brutus R, Argos M, Melkonian S, Chang-Claude J, Andrulis I, Hopper JL, John EM, Malone K, Ursin G, Gammon MD, Thomas DC, Seminara D, Casey G, Knight JA, Southey MC, Giles GG, Santella RM, Lee E, Conti D, Duggan D, Gallinger S, Haile R, Jenkins M, Lindor NM, Newcomb P, Michailidou K, Apicella C, Park DJ, Peto J, Fletcher O, dos Santos Silva I, Lathrop M, Hunter DJ, Chanock SJ, Meindl A, Schmutzler RK, Müller-Myhsok B, Lochmann M, Beckmann L, Hein R, Makalic E, Schmidt DF, Bui QM, Stone J, Flesch-Janys D, Dahmen N, Nevanlinna H, Aittomäki K, Blomqvist C, Hall P, Czene K, Irwanto A, Liu J, Rahman N, Turnbull C; Familial Breast Cancer Study, Dunning AM, Pharoah P, Waisfisz Q, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Nicolae D, Easton DF, Cox NJ, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):658-69. doi: 10.1158/1055-9965.EPI-13-0340. Epub 2014 Feb 3.

8.

Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers.

John EM, McGuire V, Thomas D, Haile R, Ozcelik H, Milne RL, Felberg A, West DW, Miron A, Knight JA, Terry MB, Daly M, Buys SS, Andrulis IL, Hopper JL, Southey MC, Giles GG, Apicella C, Thorne H; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1547-56. doi: 10.1158/1055-9965.EPI-13-0189. Epub 2013 Jul 12.

9.

Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.

Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Goodman MT, Lurie G, Chang-Claude J, Rudolph A, Kjær SK, Jensen A, Høgdall E, Bandera EV, Olson SH, King MG, Rodriguez-Rodriguez L, Kiemeney LA, Marees T, Massuger LF, van Altena AM, Ness RB, Cramer DW, Pike MC, Pearce CL, Berchuck A, Schildkraut JM, Whittemore AS; Ovarian Cancer Association Consortium.

Int J Epidemiol. 2013 Apr;42(2):579-89. doi: 10.1093/ije/dyt042.

10.

Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA.

Am J Surg Pathol. 2012 Aug;36(8):1170-7. doi: 10.1097/PAS.0b013e31825d9b8d.

11.

Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.

Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, Miron A, Andrulis IL, Hopper JL, Knight JA, Ozcelik H, Dite GS, Apicella C, Southey MC, Whittemore AS.

J Clin Oncol. 2011 Dec 1;29(34):4505-9. doi: 10.1200/JCO.2010.34.4440. Epub 2011 Oct 31.

12.

Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.

Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, West DW, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1084-91. doi: 10.1158/1055-9965.EPI-08-1090. Epub 2009 Mar 31.

13.

No evidence of familial correlation in breast cancer metastasis.

Whittemore AS, Stearman B, Venne V, Halpern J, Felberg A, McGuire V, Daly M, Buys SS.

Breast Cancer Res Treat. 2009 Dec;118(3):575-81. doi: 10.1007/s10549-009-0368-3. Epub 2009 Mar 19.

14.

Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.

John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS.

JAMA. 2007 Dec 26;298(24):2869-76.

PMID:
18159056
15.

Imputation of missing ages in pedigree data.

Balise RR, Chen Y, Dite G, Felberg A, Sun L, Ziogas A, Whittemore AS.

Hum Hered. 2007;63(3-4):168-74. Epub 2007 Feb 19.

PMID:
17310126
16.

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.

Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC; kConFab Investigators; Ontario Cancer Genetics Network Investigators, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1863-70. Epub 2006 Oct 4.

17.

No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years.

McGuire V, John EM, Felberg A, Haile RW, Boyd NF, Thomas DC, Jenkins MA, Milne RL, Daly MB, Ward J, Terry MB, Andrulis IL, Knight JA, Godwin AK, Giles GG, Southey M, West DW, Hopper JL, Whittemore AS; kConFab Investigators.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1565-7. No abstract available.

18.

Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.

Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):359-63.

19.

Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites.

Whittemore AS, Gong G, John EM, McGuire V, Li FP, Ostrow KL, Dicioccio R, Felberg A, West DW.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2078-83.

20.

Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.

McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, John EM, West DW, Whittemore AS.

Am J Epidemiol. 2004 Oct 1;160(7):613-8.

PMID:
15383404
21.

Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients.

Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS.

Am J Public Health. 2003 Oct;93(10):1753-9.

22.

Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada.

Gong G, Oakley-Girvan I, Wu AH, Kolonel LN, John EM, West DW, Felberg A, Gallagher RP, Whittemore AS.

Cancer Causes Control. 2002 Jun;13(5):471-82.

PMID:
12146852

Supplemental Content

Loading ...
Support Center